Literature DB >> 33829280

Craniosynostosis and hydrocephalus: relevance and treatment modalities.

Paolo Frassanito1, Davide Palombi2, Gianpiero Tamburrini3,2.   

Abstract

INTRODUCTION: Hydrocephalus is variously associated to syndromic craniosynostosis (CS), while it is randomly encountered in monosutural CS. Pathogenesis is still debated and reliable criteria for the diagnosis of overt hydrocephalus are lacking. Additionally, optimal treatment is controversial since it should balance the need to relieve intracranial hypertension and the risk of recurrence favored by lowering intracranial pressure.
METHODS: A thorough review of the literature has been performed. Accordingly, pathogenic theories, diagnostic issues, and treatment options on hydrocephalus presenting in the context of CS are discussed.
RESULTS: The association of hydrocephalus to simple CS is considered a fortuitous event. Its treatment is usually driven by the etiology and clinical relevance of hydrocephalus, favoring treatment before surgical correction to reduce CSF-related complications. On the other side, pathogenesis of hydrocephalus in the context of syndromic CS has been mainly related to factors that are secondary to the synostostic process, such as craniocerebral disproportion and venous hypertension. Hydrocephalus complicates 12-15% of syndromic CS, though its incidence is more relevant in FGFR2-related CS and raises up to 88% in Pfeiffer syndrome. Overt hydrocephalus should be properly differentiated by non-tense ventriculomegaly that is more frequent in Apert syndrome. Since intracranial hypertension is constant in syndromic CS even in the absence of active hydrocephalus, radiological monitoring of ventricular size along with intracranial pressure monitoring is essential. Active hydrocephalus occurs more frequently in infants, though stable ventriculomegaly may evolve into overt hydrocephalus after cranial expansion. If hydrocephalus is not clinically prominent, cranial expansion should be favored as first surgical step. Although posterior cranial expansion may address posterior cranial fossa constriction and stabilize ventricular dilation, effectiveness in long-term control of hydrocephalus is not clear. ETV is an effective treatment option, though success rate is affected by the presence of brain malformations and patient age. Extrathecal CSF shunting should be used as last resource due to the increased risk of complications in this context.
CONCLUSIONS: The pathogenesis of hydrocephalus complicating syndromic CS should be further investigated. Concomitantly, the definition of reliable diagnostic criteria is advocated in order to promptly and properly identify active hydrocephalus. Finally, treatment algorithm should refine the best timing and treatment options aiming to relieve intracranial hypertension on one side and reduce the risk of restenosis on the other side.

Entities:  

Keywords:  Chiari; Craniocerebral disproportion; Craniosynostosis; Hydrocephalus; Personalized medicine; Venous hypertension

Year:  2021        PMID: 33829280     DOI: 10.1007/s00381-021-05158-z

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  34 in total

1.  Chiari type I and hydrocephalus.

Authors:  Luca Massimi; Giovanni Pennisi; Paolo Frassanito; Gianpiero Tamburrini; Concezio Di Rocco; Massimo Caldarelli
Journal:  Childs Nerv Syst       Date:  2019-06-21       Impact factor: 1.475

Review 2.  The growth of the posterior cranial fossa in FGFR2-induced faciocraniosynostosis: A review.

Authors:  G Coll; F Abed Rabbo; V Jecko; L Sakka; F Di Rocco; M Delion
Journal:  Neurochirurgie       Date:  2019-09-23       Impact factor: 1.553

3.  The role of endoscopic third ventriculostomy in the treatment of hydrocephalus associated with faciocraniosynostosis.

Authors:  Federico Di Rocco; Carlos Eduardo Jucá; Eric Arnaud; Dominique Renier; Christian Sainte-Rose
Journal:  J Neurosurg Pediatr       Date:  2010-07       Impact factor: 2.375

Review 4.  Hydrocephalus and Chiari type I malformation.

Authors:  Concezio Di Rocco; Paolo Frassanito; Luca Massimi; Simone Peraio
Journal:  Childs Nerv Syst       Date:  2011-09-17       Impact factor: 1.475

5.  Cloverleaf skull deformity and hydrocephalus.

Authors:  Guilherme Machado; Federico Di Rocco; Christian Sainte-Rose; Philippe Meyer; Daniel Marchac; Gaëlle Macquet-Nouvion; Eric Arnaud; Dominique Renier
Journal:  Childs Nerv Syst       Date:  2011-09-17       Impact factor: 1.475

Review 6.  Hydrocephalus in craniosynostosis: a review.

Authors:  H Collmann; N Sörensen; J Krauss
Journal:  Childs Nerv Syst       Date:  2005-04-27       Impact factor: 1.475

7.  Hydrocephalus and craniosynostosis.

Authors:  G Cinalli; C Sainte-Rose; E M Kollar; M Zerah; F Brunelle; P Chumas; E Arnaud; D Marchac; A Pierre-Kahn; D Renier
Journal:  J Neurosurg       Date:  1998-02       Impact factor: 5.115

8.  Comparative three-dimensional analysis of CT-scans of the calvaria and cranial base in Apert and Crouzon syndromes.

Authors:  S Kreiborg; J L Marsh; M M Cohen; M Liversage; H Pedersen; F Skovby; S E Børgesen; M W Vannier
Journal:  J Craniomaxillofac Surg       Date:  1993-07       Impact factor: 2.078

9.  The formation of the foramen magnum and its role in developing ventriculomegaly and Chiari I malformation in children with craniosynostosis syndromes.

Authors:  Bianca F M Rijken; Maarten H Lequin; Marie-Lise C Van Veelen; Johan de Rooi; Irene M J Mathijssen
Journal:  J Craniomaxillofac Surg       Date:  2015-05-08       Impact factor: 2.078

Review 10.  Hydrocephalus and Chiari malformation pathophysiology in FGFR2-related faciocraniosynostosis: A review.

Authors:  G Coll; Y El Ouadih; F Abed Rabbo; V Jecko; L Sakka; F Di Rocco
Journal:  Neurochirurgie       Date:  2019-09-13       Impact factor: 1.553

View more
  1 in total

Review 1.  Posterior vault "free-floating" bone flap: indications, technique, advantages, and drawbacks.

Authors:  Gianpiero Tamburrini; Martina Offi; Luca Massimi; Paolo Frassanito; Federico Bianchi
Journal:  Childs Nerv Syst       Date:  2021-07-15       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.